Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma

Shaji Kumar; Katrina N. Glazebrook; Stephen M. Broski

doi:10.1016/j.cpet.2019.03.006

Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma

Shaji Kumar, Katrina N. Glazebrook, Stephen M. Broski

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Multiple myeloma is a malignancy of terminally differentiated plasma cells representing the second most common hematological malignancy. The recognition that disease outside the marrow can significantly influence the outcome of patients has highlighted the importance of imaging to define presence of tumor. Recent studies have demonstrated an added value of using imaging to assess presence of disease both inside and outside the marrow. To this end, the response criteria have been revised to include PET/computed tomography to be used in conjunction with bone marrow assessment to determine minimal residual disease status.

Original language	English (US)
Pages (from-to)	391-403
Number of pages	13
Journal	PET Clinics
Volume	14
Issue number	3
DOIs	https://doi.org/10.1016/j.cpet.2019.03.006
State	Published - Jul 2019

Keywords

Extramedullary disease
Minimal residual disease
Multiple myeloma
PET
PET/CT
Response

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2019.03.006

Cite this

@article{27240d23a6f34d1a95515580948ce6e1,

title = "Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma",

abstract = "Multiple myeloma is a malignancy of terminally differentiated plasma cells representing the second most common hematological malignancy. The recognition that disease outside the marrow can significantly influence the outcome of patients has highlighted the importance of imaging to define presence of tumor. Recent studies have demonstrated an added value of using imaging to assess presence of disease both inside and outside the marrow. To this end, the response criteria have been revised to include PET/computed tomography to be used in conjunction with bone marrow assessment to determine minimal residual disease status.",

keywords = "Extramedullary disease, Minimal residual disease, Multiple myeloma, PET, PET/CT, Response",

author = "Shaji Kumar and Glazebrook, {Katrina N.} and Broski, {Stephen M.}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = jul,

doi = "10.1016/j.cpet.2019.03.006",

language = "English (US)",

volume = "14",

pages = "391--403",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma

AU - Kumar, Shaji

AU - Glazebrook, Katrina N.

AU - Broski, Stephen M.

PY - 2019/7

Y1 - 2019/7

N2 - Multiple myeloma is a malignancy of terminally differentiated plasma cells representing the second most common hematological malignancy. The recognition that disease outside the marrow can significantly influence the outcome of patients has highlighted the importance of imaging to define presence of tumor. Recent studies have demonstrated an added value of using imaging to assess presence of disease both inside and outside the marrow. To this end, the response criteria have been revised to include PET/computed tomography to be used in conjunction with bone marrow assessment to determine minimal residual disease status.

AB - Multiple myeloma is a malignancy of terminally differentiated plasma cells representing the second most common hematological malignancy. The recognition that disease outside the marrow can significantly influence the outcome of patients has highlighted the importance of imaging to define presence of tumor. Recent studies have demonstrated an added value of using imaging to assess presence of disease both inside and outside the marrow. To this end, the response criteria have been revised to include PET/computed tomography to be used in conjunction with bone marrow assessment to determine minimal residual disease status.

KW - Extramedullary disease

KW - Minimal residual disease

KW - Multiple myeloma

KW - PET

KW - PET/CT

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=85064073468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064073468&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2019.03.006

DO - 10.1016/j.cpet.2019.03.006

M3 - Review article

C2 - 31084778

AN - SCOPUS:85064073468

SN - 1556-8598

VL - 14

SP - 391

EP - 403

JO - PET Clinics

JF - PET Clinics

IS - 3

ER -

Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this